Hormonal
Prescription weight loss medications (oral or injectable) combined with lifestyle interventions result in additional weight loss compared to lifestyle interventions alone, with newer emergent medications demonstrating up to 12.4% weight loss over 68 weeks.
If you have obesity, lifestyle changes are the foundation, but adding prescription medication can significantly boost your weight loss results (3-12%+). Don't let fear of needles or side effects stop you from discussing these options with your doctor; many patients find the benefits outweigh the manageable risks, and doctors often overestimate this fear.
The use of currently available prescription weight loss medications in Australia in conjunction with lifestyle interventions can result in an additional 3% to 9% weight loss over 12 months compared with lifestyle interventions alone... Emergent prescription weight loss medication in conjunction with lifestyle interventions has demonstrated an additional 12.4% weight loss over 68 weeks compared with lifestyle interventions alone.
Why this rating
The paper cites clinical trial data (Ref 8, 12) for efficacy claims, but the primary study is a preference survey (DCE), not a clinical trial itself.
Source
Patient and Healthcare Professional Preferences for Prescription Weight Loss Medications in Australia: Two Discrete Choice Experiments
Simon Fifer et al. · Patient Preference and Adherence · 2024
DOI 10.2147/ppa.s446106
More from this paper
- Healthcare professionals (HCPs) significantly overestimate patient fear of injectable weight loss medications, leading to under-prescription of these effective treatments.Strong
- Patients prioritize minimizing gastrointestinal side effects (nausea, diarrhea) over maximum percentage of body weight loss, whereas HCPs prioritize maximum weight loss.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →